Fairvalue-Calculator Fairvalue-Calculator

Empreendimentos Pague Menos S.A (PGMN3) Fair Value & Analysis

Healthcare · BR · Market cap R$2.8B

PriceR$3.68
Fair ValueR$7.30
Upside+98.4%
Quality95/100
Evidence: High Range R$3.71 – R$9.48

Analysis

Empreendimentos Pague Menos S.A (PGMN3) currently trades at R$3.68, while our model-based Fair Value estimate is R$7.30 — implying the stock looks roughly 98.4% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

Empreendimentos Pague Menos S.A. engages in the retail sale of medicines, perfumeries, and personal hygiene and beauty products in Brazil. The company offers medicines and health care products; personal hygiene products, including deodorant, intimate care, and oral hygiene; foot, hair, face, and hand care products; dermo and beauty products; and repellent, diaper, cloth, and food products, as well as other accessories for moms and babies. The company also offers vaccines, clinical analysis tests, and basic health services; clothing and accessories, supplements, first aid, food and drinks, chocolates, ice creams, popsicles, toys, pet and home products, laptop accessories, utilities, and others; and cereals, fibers, vitamins and minerals, first aid, and herbal medicines and natural products. It sells its products through retail stores and online. Empreendimentos Pague Menos S.A. was incorporated in 1981 and is based in Fortaleza, Brazil.

Open the full interactive analysis →

Similar stocks

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.